Dr. Vladimir Cmiljanovic is a renowned serial biotech entrepreneur, cancer scientist, and medicinal chemist with over 15 years of experience in oncology drug development.

Dr. Natasa Cmiljanovic is a dynamic and accomplished professional, serving as the Chief Operating Officer and Founder of Swiss Rockets. With over a decade of invaluable experience in oncology drug development, Natasa's background as a medicinal chemist and clinical scientist makes her a driving force in the field.

Andreas has more than 20 years of experience as the CFO of public and private multinational companies, including 15 years in the biotech industry.

Nenad Paunovic is an executive specialized in business development through innovative strategies and business models. He has 30 years of diverse professional experience, from startup to government worlds.

Dr. Carlo Durrer is a leader with over 30 years of international experience in pharmaceutical manufacturing, quality, and supply chain, mainly in global research-based companies, as well as generics companies. His work as a consultant additionally enlarged his expertise.

Dr. Bruno Osterwalder is an esteemed figure in the realm of hematology and oncology, with a wealth of experience spanning 15 years in academic clinical practice. With Swiss board certifications, his journey has been a testament to his expertise in internal medicine, hematology, and oncology.

Dr. Doriano Fabbro is a renowned drug discovery and kinase expert with more than 20 years’ experience in the pharmaceutical industry, following 10 years in academia. Until 2005, Doriano was an Executive Director for the Oncology Drug Discovery Division of the Novartis Institute for Biomedical Research (NIBR) in Basel, Switzerland and was a member of the NIBR Oncology Advisory Board overseeing the oncology portfolio from target discovery to clinical development.

Dr. Milan Crnogorac is an experienced executive responsible for providing strategic, financial and operational leadership for the Technical Operations, Project Management and CapEx spending.